baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Abeona Therapeutics/ US00289Y2063 /

6/7/2024 9:59:43 PM	Chg. 0.00	Volume	Bid-	Ask-	High	Low
4.28USD	0.00%	9,059 Turnover: 38,766.41	-Bid Size: -	-Ask Size: -	4.35	4.25

GlobeNewswire 6/5 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeut...

GlobeNewswire 6/3 Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 5/28 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeut...

GlobeNewswire 5/28 Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire 5/21 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeut...

GlobeNewswire 5/15 Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress

GlobeNewswire 5/12 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeut...

GlobeNewswire 5/7 Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 5/6 Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

GlobeNewswire 5/3 Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-F...

GlobeNewswire 5/1 SHAREHOLDER ALERT: Abeona Therapeutics Investigated by Block & Leviton For Potential Securities Law ...

GlobeNewswire 4/25 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeut...

GlobeNewswire 4/23 SHAREHOLDER ALERT: Abeona Therapeutics Investigated by Block & Leviton For Potential Securities Law ...

GlobeNewswire 4/22 Abeona Therapeutics Provides Regulatory Update on Pz-cel

GlobeNewswire 4/1 Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 3/18 Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspect...

GlobeNewswire 3/5 Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 2/29 PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day

GlobeNewswire 2/7 Artios Pharma Strengthens Financial Leadership with Appointment of Christine Silverstein as Chief Fi...

GlobeNewswire 2/1 Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 2/1 Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)

GlobeNewswire 1/8 Abeona Therapeutics Announces $50 Million Credit Facility

GlobeNewswire 12/15/2023 Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 11/27/2023 Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Ap...

GlobeNewswire 11/13/2023 Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments

Abeona Therapeutics/ US00289Y2063 /

If you wish to receive reply to your feedback, please provide your email address.